Treace Unveils Six Bunion Treatment Innovations, Reports 8.4% Recurrence at 48 Months
Treace Medical Concepts revealed six product innovations at the ACFAS 2026 conference, including SpeedTMT™ fixation implant, Lightning™ instrumentation, Nanoplasty®, Percuplasty™, SpeedMTP® fusion system, and IntelliGuide® PSI. Interim ALIGN3D™ study data on 146 patients showed an average weight-bearing return at 8.4 days and an 8.4% radiographic recurrence rate at 48 months.
1. Product Innovations at ACFAS 2026
Treace showcased six new technologies at the American College of Foot and Ankle Surgeons conference: SpeedTMT™ Rapid Compression Implant combining dynamic fixation with locking screws, Lightning™ instrumentation for faster 3D correction, Nanoplasty® MIS bunion correction, Percuplasty™ percutaneous system, SpeedMTP® fusion platform, and IntelliGuide® patient-specific 3D guides.
2. ALIGN3D™ Clinical Interim Results
The ALIGN3D™ Lapiplasty® study presented interim analysis of 146 of 173 patients with four-year follow-up. Data revealed weight-bearing return in a walking boot at 8.4 days on average, an 8.4% recurrence rate (HVA>15°) at 48 months, and a 95% lower recurrence risk when tibial sesamoid position was corrected to 3 or less.
3. MTA3D™ and SpeedMTP® Study Updates
The MTA3D™ Adductoplasty® interim analysis covered 33 of 60 patients at one year and 14 of 60 at two years, showing 7.9 days to weight bearing and sustained radiographic correction with significant pain and functional improvements. A separate retrospective poster (SCI765) evaluated SpeedMTP® first MTP fusion outcomes over six months, highlighting healing and fusion success metrics.